2.7.4.9: dTMP kinase
This is an abbreviated version!
For detailed information about dTMP kinase, go to the full flat file.
Reaction
Synonyms
ATP: TMP phosphotransferase, Cdc8, deoxythymidine 5'-monophosphate kinase, deoxythymidine monophosphate kinase, dTMP kinase, dTMP kinases, dTMPK, human thymidine monophosphate kinase (hTMPK), kinase, thymidine monophosphate (phosphorylating), kinase, thymidylate (phosphorylating), ORF454, PfTMK, S. aureus thymidylate kinase, thymidine 5'-monophosphate kinase, thymidine kinase, thymidine monophosphate kinase, thymidylate kinase, thymidylate monophosphate kinase, thymidylic acid kinase, thymidylic kinase, TK1, TMK, TMP kinase, TMPK, TMPKmt, TTHA1607, TYMK
ECTree
Advanced search results
Application
Application on EC 2.7.4.9 - dTMP kinase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
additional information
-
Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) recently emerged as a potentially attractive target for the design of a novel class of antituberculosis agents.
potential target for antituberculosis drugs
drug development
potential target for the development of antituberculosis drugs
drug development
-
potential target for the development of new antituberculosis drugs due to the low sequence similarity with the human enzyme
drug development
potential target for the development of new antituberculosis drugs due to the low sequence similarity with the human enzyme
drug development
-
potential targets for the development of antiviral and cancer therapies
the enzyme is a promising target for developing drugs against tuberculosis because the configuration of its active site is unique in the TMPK family
medicine
-
enzyme/prodrug combination for selectively inducing apoptosis in lentiviral vector-transduced cells, based on designed variants of human thymidylate kinase that effectively phosphorylate 3'-azido-3'-deoxythymidine. Mechanism involves apoptosis induction via disruption of the inner membrane potential and activation of caspase-3. Low-dose 3'-azido-3'-deoxythymidine administration to non-obese diabetic/severe combined immunodeficiency mice injected with the engineered cells suppresses tumor growth
medicine
-
introduction of an engineered, highly active dTMP kinase into T cells for more efficient conversion of the 3'-azido-3'-deoxythymidine prodrug to its diphosphorylated form and blocking replication of formerly 3'-azido-3'-deoxythymidine resistant HIV. Combined treatment of HIV-infected T-cells with 3'-azido-3'-deoxythymidine and the engineered thymidylate kinases restores 3'-azido-3'-deoxythymidine-induced repression of viral production
medicine
-
introduction of an engineered, highly active dTMP kinase into T cells for more efficient conversion of the 3'-azido-3'-deoxythymidine prodrug to its diphosphorylated form and blocking replication of formerly 3'-azido-3'-deoxythymidine resistant HIV. Combined treatment of HIV-infected T-cells with 3'-azido-3'-deoxythymidine and the engineered thymidylate kinases restores 3'-azido-3'-deoxythymidine-induced repression of viral production
medicine
-
silencing of expression in p53-/- and in p53+/+ colon cancer cells by lentiviral-based small hairpin RNA results in decrease of the dTTP pool without affecting p53 expression and generating cytotoxicity. Thymidylate kinase knock-down increases doxorubicin sensitivity dramatically in p53-proficient, p53-null HCT-116,and LoVo colon cancer cells. The decrease in the dTTP pool augments the DNA damage response and enhances apoptotic induction after exposure to low-dose doxorubicin, leading to cell death
medicine
-
bystander cell killing contributes to tumor regression in a xenograft model relying on the delivery of expression of the thymidylate kinase suicide gene into tumors via direct intratumoral injection of recombinant therapeutic lentivirus. The thymidylate kinase/azidothymidine enzyme-prodrug axis can be effectively utilized in suicide gene therapy of solid tumors